Myriad Group AG

MYRN

CH0019624805

Software

Delayed Swiss Exchange Other stock markets			5-day change	1st Jan Change
- ^CHF	-.--%		-27.92%	-62.93%

04-11	Syncona to Sell Stake in Portfolio Company to Century Therapeutics	MT
02-20	Syncona’s Takeover of Freeline Therapeutics Becomes Effective	MT

Myriad Group AG Provides Un-Audited Preliminary Earnings Guidance for the Year Ended December 31, 2014

February 24, 2015 at 01:30 am

Myriad Group AG provided un-audited preliminary earnings guidance for the year ended December 31, 2014. For the year, the company expected total revenue of USD 40.2 million, EBITDA USD of 11.1 million to USD 12.8 million, adjusted EBITDA of USD 7.5 million to USD 7.8 million, IFRS profit from operations USD 7.3 million to USD 9.0 million.

Latest news about Myriad Group AG

Syncona to Sell Stake in Portfolio Company to Century Therapeutics	04-11	MT
Syncona’s Takeover of Freeline Therapeutics Becomes Effective	02-20	MT
Syncona's Fiscal Q3 NAV Declines	02-08	MT
Syncona to Take Over Freeline Therapeutics	11-22	MT
Syncona Swings to Fiscal H1 Loss; Invest Income Falls	11-16	MT
Earnings Flash (SYNC.L) SYNCONA Posts Fiscal H1 Loss GBX-8.01	11-16	MT
Syncona Submits Takeover Bid for Freeline Therapeutics	23-10-18	MT
Syncona Launches Up to GBP40 Million Share Buyback Program	23-09-29	MT
Syncona Flags GBP55 Million Valuation Impact as Novartis' Stops Eye Disease Drug Development	23-09-11	MT
Myriad : Syncona's Gyroscope Therapeutics Says Interim Data Shows GT005 Well Tolerated in Patients With Geographic Atrophy	21-02-12	MT
Myriad : Syncona Expands Investment In Quell Therapeutics By $35 Million	21-02-11	MT
Myriad : Syncona's Expects COVID-19 to Not impact Valuations as Net Asset Value Declines in Q4 2020	21-02-11	MT
Myriad : Syncona's Autolus Prices $100 Million Public Offering in US	21-02-10	MT
Myriad : Syncona Unit Freeline Therapeutics Makes Changes In Clinical Development Plan for Hemophilia B Trial	21-02-08	MT
Myriad : Syncona's Achilles Therapeutics to Continue Clinical Trials on T Cell Therapies to Treat Solid Tumors	21-02-05	MT
Myriad : Syncona's Achilles Therapeutic Mulls IPO in US	21-02-05	MT
Myriad : Syncona Portfolio Company Autolus to Cut 20% Workforce in Q1	21-01-06	MT
Myriad : Syncona Launches New Gene Therapy Company	20-11-19	MT
Myriad : Earnings Flash (SYNC.L) SYNCONA Posts H1 EPS GBX17.86	20-11-19	MT
Myriad Group AG(SWX:MYRN) dropped from Swiss Performance Index (Price Return)	18-04-30	CI
Myriad Group AG Provides Earnings Guidance for the Year Ended December 31, 2017	18-03-20	CI
Myriad Group AG(SWX:MYRN) dropped from S&P Global BMI Index	17-09-18	CI
Myriad Group AG Announces Board Appointments	17-08-24	CI
Myriad Group AG Announces Earnings Results for the Half Year of 2017	17-07-27	CI
Myriad Group Announces Resignation of Mauro Saladini from Board of Directors	17-04-27	CI

Chart Myriad Group AG

Duration

Period

More charts

Company Profile

Myriad Group AG is a Switzerland-based company. The Company provides mobile USSD technology, empowering enterprises to deliver new mobile services to enhance customer engagements and improve service delivery, regardless of device or connection. It products and services are integrated within mobile networks, exposing capabilities and core network assets to enterprises, offering unparalleled reach, security, and service.

Sector

Software

More about the company

Sector Other Software

	1st Jan change	Capi.
MYRIAD GROUP AG	-62.93%	0
SYNOPSYS INC.	+6.90%	86.53B
CADENCE DESIGN SYSTEMS, INC.	+2.58%	78.44B
DASSAULT SYSTÈMES SE	-16.20%	53.55B
PALANTIR TECHNOLOGIES INC.	+24.64%	48.39B
THE TRADE DESK, INC.	+27.25%	45.84B
ATLASSIAN CORPORATION	-35.05%	41.75B
SEA LIMITED	+65.11%	38.57B
TAKE-TWO INTERACTIVE SOFTWARE, INC.	-0.88%	27.38B
ROBLOX CORPORATION	-27.15%	21.22B

Other Software

Myriad Group AG

Equities

MYRN

CH0019624805

Software

Myriad Group AG Provides Un-Audited Preliminary Earnings Guidance for the Year Ended December 31, 2014

Latest news about Myriad Group AG

Chart Myriad Group AG

Company Profile

Sector Other Software